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Introduction {#sec1}
============

Triple-negative breast cancer (TNBC), which accounts for 15%--20% of breast cancer cases, is a challenging disease to treat because of tumor heterogeneity, intrinsic resistance to conventional chemotherapy, and lack of targeted therapies ([@bib1], [@bib31]). Although optimization of currently available chemotherapeutic agents for TNBC patients has improved patient outcome, novel targeted therapies are urgently needed to improve patient survival ([@bib26]). Since their discovery through genetic "lineage retracing" in squamous skin tumors, glioblastomas (GBM), and intestinal adenomas, cancer stem cells (CSCs) within the bulk tumor have been associated with multiple phenotypes including chemoresistance, clonogenic potential, and hierarchical tumor growth ([@bib11], [@bib5], [@bib40]). In this study, we investigated a breast cancer stem cell (BCSC) gene signature, focusing on genes responsible for cancer stem cell self-renewal, and identified *HN1L* as a gene critical for BCSC maintenance.

We have previously published a BCSC gene signature by comparing CSCs and non-CSCs isolated from patient biopsies ([@bib8], [@bib9]). This approach narrowed down the number of genes that may influence CSC growth from a genome-wide level to only 493 genes. We then identified 13 genes to be CSC-regulating genes, by screening the effects of short hairpin RNA (shRNA) gene silencing on the mammosphere-forming ability of TNBC cell lines. We recently reported the CSC-regulating roles of *RPL39* and *MLF2*, two candidate genes among the 13 CSC genes ([@bib9]).

*HN1L* is one of the top 13 CSCs genes whose functions have not been well characterized ([@bib32]). Previously, *HN1L*, also known as *L11*, was reported with another 18 uncharacterized genes to be overexpressed in non-small-cell lung cancer ([@bib35]). In the report, *L11* overexpression was identified in various cancer types, but the highest expression was found in breast and uterine cancer. While *HN1L* also contributes to embryonic development ([@bib53]), not much is known about its cellular function since it has no homology with existing protein domain sequences ([@bib32]). Here, we describe the essential role of *HN1L* in BCSC maintenance and explore its mechanism of action in this context. A comprehensive evaluation of *HN1L* function in patient-derived xenograft (PDX) tumors reveals that multiple pathways are regulated by *HN1L*, in which *STAT3* signaling is the key mediator. Taken as a whole, our data reveal the crucial upstream role that *HN1L* plays in promoting multiple cellular survival pathways via influence on the BCSC transcriptome.

Results {#sec2}
=======

High HN1L Expression Correlates with Poor Prognosis in TNBC {#sec2.1}
-----------------------------------------------------------

*HN1L* is one of the top candidate genes among the selected 13 genes ([Table S1](#mmc1){ref-type="supplementary-material"}), whose gene silencing significantly reduced the mammosphere-forming ability of MDA-MB-231 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}). Thus, we decided to investigate the expression patterns of *HN1L* in TCGA breast cancer patient database with RNA sequencing (RNA-seq) information. Among the 960 breast cancer patients, approximately 25% of patients have alterations in the *HN1L* gene, consisting of mostly mRNA upregulation or gene copy number amplifications ([Figure 1](#fig1){ref-type="fig"}A). We also found that breast tumors express significantly higher levels of *HN1L* mRNA compared with normal breast tissue ([Figure 1](#fig1){ref-type="fig"}B). Interestingly, we found, using the TCGA dataset, that the overexpression of *HN1L* was correlated with shorter patient survival (p = 0.0368) only in TNBC ([Figure 1](#fig1){ref-type="fig"}C), while no survival difference was seen in non-TNBC ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We confirmed the similar survival correlation between *HN1L* expression and the shorter survival trend in TNBC patients using the Curtis patient dataset ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Additionally, using the previously reported TNBC cohorts ([@bib6]), we confirmed that TNBC patients with high levels of *HN1L* had shorter relapse-free survival than patients with low HN1L levels (p \< 0.01) ([Figure 1](#fig1){ref-type="fig"}D). These results demonstrate that *HN1L* is upregulated in breast cancer and that its enhanced expression correlates with poor clinical outcomes in TNBC patients. Moreover, we recently identified two missense mutations in *HN1L* (P20L and A106V; [Table S2](#mmc1){ref-type="supplementary-material"}) from previously published RNA-seq data ([@bib9]). Based on these findings, we recognized *HN1L* as a potential therapeutic target and chose to study its role in TNBC in greater detail.Figure 1Enhanced Expression of *HN1L* Correlates with Poor Clinical Outcome in TNBC Patients(A) Data acquired from cBioPortal for Cancer Genomics showed *HN1L* alteration in 960 breast cancer patients.(B) The expression of *HN1L* mRNA is higher in breast tumors than in normal samples (p \< 0.0001) in both TCGA and Curtis breast cancer gene expression databases.(C and D) Higher *HN1L* expression portends significantly poorer overall survival in TCGA TNBC patients (C) and relapse-free survival of previously published TNBC patients (D) ([@bib38], [@bib6]).Error bars represent the SD.

Silencing HN1L Reduces the CSC Population in TNBC Cell Lines {#sec2.2}
------------------------------------------------------------

We then confirmed that protein levels of *HN1L* were higher in CSC-enriched populations, compared with non-CSCs. CD44^+^/CD24^−/low^ population in sorted SUM159 cells only, but not in MDA-MB-231, as more than 90% cells in the MDA-MB-231 cell line are CD44^+^/CD24^−/low^ ([Figure 2](#fig2){ref-type="fig"}A). Also, TNBC cell lines with stable *HN1L* gene silencing showed reduced CD44^+^/CD24^−/low^ population and impaired mammosphere-forming ability (MSFE), implying that *HN1L* may play a significant role in maintaining CSCs ([Figures 2](#fig2){ref-type="fig"}B--2D). Knockdown of *HN1L* also impaired cell migration as analyzed by a transwell assay ([Figure 2](#fig2){ref-type="fig"}E). To better represent the 3D tumor microenvironment, we first allowed MDA-MB-231 cells to form spheroids and then embedded them in Matrigel, permitting only invasive cells to invade. Stable *HN1L* knockdown cells remained as cell aggregates without invasion into the surrounding matrix, while control cells were more invasive and formed spindle-like protrusions ([Figure 2](#fig2){ref-type="fig"}F). No invasion was observed in either control or *HN1L* gene knockdown SUM159 cells (data not shown). In addition, we further confirmed the gene silencing effect (of *HN1L*) on the CD44^+^/CD24^−/low^ population and MSFE of three TNBC cell lines using small interfering RNAs (siRNAs) targeting two different regions of *HN1L* ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). These results suggest that HN1L may have an important role in multiple CSC functions, including cell migration and invasion.Figure 2*HN1L* Is Overexpressed and Required for BCSCs(A) BCSCs were enriched by either flow sorting (CD44^+^/CD24^−/low^) or forming mammospheres. Increased HN1L levels were detected in the BCSC-enriched population by immunoblotting. Others, all other cell populations except the CD44^+^/CD24^−/low^ BCSC population; MS, mammosphere; PT, prantel cells. β-Actin served as a loading control. n = 3 independent experiments.(B) Western blot showing HN1L knockdown by shRNA in TNBC cell lines. n = 3 independent experiments.(C) *HN1L* shRNA transduction decreased CD44^+^/CD24^−/low^ population upon flow-cytometry analysis. n = 3 independent experiments with 3 technical replicates; ^∗^p \< 0.05.(D) *HN1L* shRNA transduction reduced MSFE. n = 3 independent experiments with 6 technical replicates; ^∗^p \< 0.05.(E and F) *HN1L* shRNA transduction reduced cell migration (E) and 3D cancer invasion (F). n = 3 independent experiments with 3 technical replicates; ^∗^p \< 0.05.Error bars represent the SD.

Increase in the Cancer Stem Cell Population with HN1L Overexpression *In Vitro* {#sec2.3}
-------------------------------------------------------------------------------

Because depletion of HN1L reduced CSC function, we hypothesized that *HN1L* overexpression in SUM159 and MDA-MB-468 cells would also increase CSCs. Indeed, overexpression of FLAG-tagged *HN1L* significantly increased the CD44^+^/CD24^−/low^ population from 66% to 87% in SUM159 cells (p \< 0.0001) and from 2.3% to 7.6% in MDA-MB-468 cells (p \< 0.0001), when compared with the respective control cells transfected with empty vector. The MDA-MB-231 cell line was not used because more than 90% of cells are CD44^+^/CD24^−/low^ ([Figure 3](#fig3){ref-type="fig"}A). The increased BCSC population, via *HN1L* overexpression, was positively correlated with increased MSFE ([Figure 3](#fig3){ref-type="fig"}B) and decreased sensitivity to docetaxel ([Figure 3](#fig3){ref-type="fig"}C). MDA-MB-468 cells were equally sensitive to docetaxel regardless of the overexpression of *HN1L*. Additionally, we observed enhanced cell migration and invasion with *HN1L* overexpression, which was subsequently decreased to control levels by the co-transfection of siRNAs against *HN1L* in three different cell lines ([Figure 3](#fig3){ref-type="fig"}D). Immunoblotting confirmed the overexpression of FLAG-HN1L and also its siRNA-mediated knockdown ([Figure 3](#fig3){ref-type="fig"}E) over the 72 hr of experimental duration. Cells transfected with the overexpression plasmid and the scrambled siRNAs served as a control for overexpressed *HN1L* at 72 hr and were compared with cells co-transfected with the overexpression plasmid and the silencing siRNAs for *HN1L* ([Figure 3](#fig3){ref-type="fig"}E). These results indicate that increased HN1L expression induced the CD44^+^/CD24^−/low^ population, increased MSFE and invasive potential, and generated chemoresistance in the cancer cells.Figure 3*HN1L* Overexpression Increases the BCSC Population *In Vitro*TNBC cells were transfected with a plasmid to overexpress Myc-DDK tagged HN1L.(A) Flow analysis revealed that the CD44^+^/CD24^−/low^ population increased with HN1L overexpression (OE) after 48 hr. n = 3 independent experiments with 3 technical replicates. ^∗∗∗^p \< 0.001. The data present average results of three biological repeats with SD.(B) Secondary MSFE increased with *HN1L* overexpression. n = 3 independent experiments with 12 technical replicates.(C) Cells with or without *HN1L* overexpression were treated with varying doses of docetaxel for 48 hr. MTT assays showed decreased sensitivity of *HN1L*-overexpressed cells to docetaxel treatment. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. n = 3 independent experiments with 8 technical replicates.(D) *HN1L* overexpression increased cell motility, which was inhibited by the simultaneous *HN1L* gene silencing (^∗^p \< 0.05). n = 3 independent experiments with 3 technical replicates.(E) Both endogenous HN1L and overexpressed Myc-DDK(FLAG)-tagged HN1L levels were detected after overexpression and then were reduced with *HN1L* siRNA treatment by 48 hr. β-Actin served as a loading control. Cell migration/invasion in BME-coated Boyden chambers was examined. EV, empty mock plasmid; OE-*HN1L*, *HN1L* overexpression plasmid; siScr, scrambled siRNA; *HN1L* siRNA, siRNA against *HN1L*.Error bars represent the SD.

HN1L Depletion Reduces the Cancer Stem Cell Population and Lung Metastasis *In Vivo* {#sec2.4}
------------------------------------------------------------------------------------

We examined the treatment efficacy of *HN1L* siRNA in MDA-MB-231 and SUM159 TNBC cell line xenograft tumor models. Neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes were used for efficient *in vivo* siRNA delivery ([@bib42], [@bib43]). We initially treated MDA-MB-231 tumor-bearing mice with *HN1L* liposomal siRNA for a short-term study of 21 days. We confirmed the *in vivo* gene silencing effects using immunohistochemistry ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Significant reductions in tumor volume, CD44^+^/CD24^−/low^ population, and secondary MSFE were observed with HN1L knockdown ([Figures 4](#fig4){ref-type="fig"}A--4C), and a statistically non-significant decrease in ALDF^+^ cells was also apparent ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Similar results were observed in the SUM159 xenograft model ([Figures S3](#mmc1){ref-type="supplementary-material"}F--S3H). We confirmed with a limiting dilution assay (LDA) that HN1L is critical for maintenance of BCSCs in TNBC. The gene silencing by *HN1L* siRNA-DOPC decreased the BCSC frequencies in MDA-MB-231 cells about 2- to 3-fold compared with the scrambled siRNA-DOPC as measured by these LDAs([Figure 4](#fig4){ref-type="fig"}D).Figure 4*HN1L* siRNA Treatment in MDA-MB-231 Xenografts and BCM2665 Patient-Derived Xenografts Decreases BCSC FunctionMDA-MB-231 cells were injected, and BCM2665 tumor pieces were orthotopically transplanted into SCID-Beige mice. Mice (n = 10 per group) were injected with the respective DOPC liposomal siRNA (scrambled siRNA or HN1L siRNA) by intraperitoneal injection at 5 μg/injection twice a week (A and E). Tumor volumes were measured twice per week for 3 weeks, and tumors were collected after euthanizing animals for fluorescence-activated cell sorting analysis of CD44^+^/CD24^−/low^ (B) or ALDF + CSCs (F). The remaining tumor cells were used to assess mammosphere-forming ability (C and G). Another set of animals with BCM2665 tumors were randomized into three groups (n = 15): docetaxel + vehicle (PBS), docetaxel + scrambled siRNA, docetaxel + *HN1L* siRNA (H). siRNAs were delivered by intraperitoneal injection at 5 μg/injection twice a week for 6 weeks. All animals received docetaxel (33.3 mg/kg at days 1, 15, and 30). At the end of the study, tumors were collected from euthanized mice and subjected to limiting dilution assays (D and I).Error bars in (B), (C), (F), and (G) represent the SD. Error bars in (A), (E), and (H) represent the SEM. ^∗^p \< 0.05.

We further evaluated the effects of silencing *HN1L* on BCSCs using a patient-derived TNBC xenograft model, BCM2665, with known drug resistance to docetaxel up to 20 mg/kg ([@bib50], [@bib9]). Unlike the cell line tumor models, *HN1L* siRNA-DOPC as a single agent did not affect tumor volume in a 21-day study ([Figure 4](#fig4){ref-type="fig"}E), although we confirmed the gene silencing effect by western blot analysis of tumors from each treatment group ([Figure S4](#mmc1){ref-type="supplementary-material"}A). This result is likely due to the fact that the proportion of BCSCs in primary PDX tumors is low compared with cell lines such as MDA-MB-231. Previously, CSC in BCM2665 was defined by the ALDF and MSFE due to lack of CD44^+^/CD24^−/low^ subpopulation ([@bib9]). Despite there being no effect on tumor growth, we observed a reduction of the ALDF^+^ population and a significant decrease in MSFE at the end of *HN1L* siRNA treatment ([Figures 4](#fig4){ref-type="fig"}F and 4G), suggesting an effect on BCSC self-renewal function. Based on these results, we examined whether silencing *HN1L* would increase the sensitivity of drug-resistant BCM2665 to docetaxel (33.3 mg/kg) by targeting the BCSC subpopulation. As expected, the combination of *HN1L* siRNA-DOPC and docetaxel significantly inhibited tumor growth compared with docetaxel treatment alone ([Figure 4](#fig4){ref-type="fig"}H). Using an LDA, we confirmed that the synergistic effect of the combination treatment with a reduction in BCSC subpopulation. Tumors transplanted after the combination treatment showed a significant decline in BCSCs as indicated by decreased rates of tumor initiation and BCSC frequency by these assays ([Figure 4](#fig4){ref-type="fig"}I). Additionally, combination treatment with a lower docetaxel dose schedule (20 mg/kg) sensitized MDA-MB-231 cells to chemotherapy. While docetaxel alone did not significantly affect tumor growth, the combination treatment caused a statistically significant tumor growth delay ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

BCSCs have been found to drive metastasis ([@bib27], [@bib28]). We investigated whether suppression of *HN1L* was able to impair lung metastasis in TNBC xenografts using a luciferase-tagged MDA-MB-231 cell line that develops spontaneous lung metastases from the orthotopically transplanted primary tumor ([@bib7]). *HN1L* siRNA-DOPC was administered as either a single agent or in combination with docetaxel. The results indicated that delivery of *HN1L* siRNA-DOPC alone (or in combination with docetaxel) reduced tumor burden in lungs compared with scrambled siRNA (or scrambled siRNA with docetaxel) and significant reduction was seen only for the combination treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These results suggest that *HN1L* inhibition not only decreased the BCSC population and increased chemosensitivity, but also reduced metastasis from primary tumors to lungs *in vivo*. Altogether, these data indicate that *HN1L* is a promising target for patients with TNBC for whom chemotherapy is the only option.

Inhibition of HN1L Is Associated with Better TNBC Patient Prognosis {#sec2.5}
-------------------------------------------------------------------

Since HN1L depletion reduces cancer burden in our models, we sought to determine genes that may be influenced by the absence of HN1L. The corresponding gene signature could then be correlated with patient survival to determine whether the altered gene set can predict prognosis. To explore gene expression profiles when *HN1L* expression is silenced, we performed microarray analysis on BCM2665 tumor samples from scrambled siRNA- and *HN1L* siRNA-treated xenografts (n = 10). This analysis identified 74 upregulated and 62 downregulated genes under *HN1L* knockdown conditions (fold change \> 1.5, p \< 0.05) ([Figure 5](#fig5){ref-type="fig"}A). This altered gene set was defined as the *HN1L* knockdown gene signature. On applying this gene signature to the 383-patient cohort, we found that patients with an activated *HN1L* knockdown gene signature demonstrated a significantly longer relapse-free survival (log-rank test, p = 0.00583) ([Figure 5](#fig5){ref-type="fig"}B). These findings reaffirm the effectiveness of HN1L inhibition on TNBC progression and indicate that *HN1L*-mediated signaling pathways correlate with TNBC patient survival. With further validation, this signature may be a useful prognostic marker in the future.Figure 5Genes Regulated by HN1L Are Enriched for the *JAK-STAT3* Pathway(A) Five tumor samples from scrambled siRNA-treated mice and *HN1L* siRNA-treated mice were used for microarray analysis. Genes significantly changed (p \< 0.05, fold change \> 1.5) were identified as the *HN1L* knockdown gene signature and are shown in the heatmap.(B) The *HN1L* knockdown gene signature correlated with significantly improved relapse-free survival in a cohort of 383 TNBC patients.(C) Top canonical pathways identified by IPA based on microarray analysis of siRNA-treated BCM2665 xenograft tumors. The red box indicates the most significantly altered signaling pathway.(D) Broad Institute GSEA analysis of *JAK2-STAT3* pathway in BCM2665 xenografts treated with siRNA against *HN1L*, showing that the pathway was significantly downregulated.(E) Mutual exclusivity analysis of *HN1L*, *LEPR*, and *STAT3* in the TCGA breast cancer database demonstrated a significant tendency toward co-occurrence for *HN1L* with *LEPR* and *STAT3*. mRNA expression (microarray) and protein/phosphoprotein level (RPPA) data profiles were selected in all 1,104 tumor samples from cBioPortal for Cancer Genomics to generate the table.

HN1L Regulates an LEPR-STAT3 Signaling Pathway {#sec2.6}
----------------------------------------------

We performed a pathway enrichment analysis using Ingenuity Pathway Analysis (IPA) on the identified gene signature to identify the top signaling pathways. Using this method, the most significantly altered gene set identified was leptin signaling ([Figure 5](#fig5){ref-type="fig"}C). Leptin receptor (LEPR) is well known to be upregulated and essential in maintaining BCSCs in TNBC ([@bib13], [@bib52]). *STAT3* signaling is a key downstream mediator of *LEPR* pathways ([@bib33], [@bib34], [@bib4]). We then examined *JAK-STAT* pathway activity with gene set enrichment analysis (GSEA), whereby a significant reduction of *JAK-STAT* signaling was observed in *HN1L* knockdown tumors ([Figure 5](#fig5){ref-type="fig"}D). These results led us to investigate the correlation between *HN1L*, *LEPR*, and *STAT3*. A mutual exclusivity analysis using microarray and reverse-phase protein assay (RPPA) data on 1,104 breast cancer patients from TCGA revealed that *HN1L* was highly statistically likely to act through the same signaling pathway with *LEPR* and *STAT3* ([Figure 5](#fig5){ref-type="fig"}E).

HN1L Is a BCSC Transcription Regulator of the LEPR-STAT3 Signaling Pathway {#sec2.7}
--------------------------------------------------------------------------

To confirm the relevance of this pathway *in vitro*, *HN1L* silencing experiments using siRNA were performed in SUM159, MDA-MB-231, and MDA-MB-468 cells. LEPR and phospho-STAT3, but not leptin, were reduced at the protein level upon *HN1L* silencing ([Figure 6](#fig6){ref-type="fig"}A). Consistently, transfection with a *HN1L* overexpression plasmid for 48 hr increased the expression of phospho-STAT3, STAT3, LEPR, and leptin ([Figures 6](#fig6){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A). Also, *LEPR* depletion inhibited STAT3 activation while not affecting HN1L levels ([Figure 6](#fig6){ref-type="fig"}C), suggesting that HN1L may work upstream of LEPR. Similar results were seen *in vivo*, in which PDX tumors depleted of HN1L had decreased LEPR and STAT3 signaling ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Together, these data support the existence of an HN1L-LEPR-STAT3 pathway.Figure 6HN1L Activates the STAT3 Pathway by Regulating LEPR Expression(A--C) Western blot data assessing HN1L, LEPR, and STAT3 signaling in TNBC cell lines under different treatment conditions; siScr, scrambled siRNA; siHN1L, silencing RNA against HN1L. β-Actin served as a loading control. i, HN1L-Myc-DDK; ii, endogenous HN1L.(D) Real-time PCR results demonstrating silencing effects of *HN1L* on *STAT3* and *LEPR*. n = 3 independent experiments with 3 technical replicates.(E) *STAT3* transcriptional activity was determined by Cignal luciferase reporter assay using *STAT3* reporter in SUM159 cells transfected with the indicated amounts of the *HN1L* overexpression plasmid. EV, empty vector. n = 3 independent experiments with 3 technical replicates.(F) Real-time PCR on transcription factors that are downstream of *STAT3* and are essential for stem cell function was performed in *HN1L* knockdown SUM159 cells. n = 3 independent experiments with 3 technical replicates.(G and H) Silencing *LEPR* decreased cell migration/invasion and MSFE in SUM159 cells. n = 3 independent experiments with 3 technical replicates in migration/invasion assay. n = 3 independent experiments with 12 technical replicates in MSFE assay.Error bars represent the SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To determine whether HN1L influences the transcription of *STAT3* and *LEPR*, we performed qRT-PCR in MDA-MB-231 cells after silencing or overexpressing *HN1L*. We limited our investigation to *STAT3* and *LEPR* because these two genes were commonly affected by the *HN1L* gene silencing and overexpression. We found that silencing *HN1L* reduced the mRNA levels by half for both *STAT3* and *LEPR* ([Figures 6](#fig6){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B) while the overexpression caused a 2.5-fold increase in the transcription of the two genes compared with the respective controls ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We further confirmed the transcriptional activity of *HN1L* using a *STAT3* luciferase reporter system. *STAT3*-dependent transcription was strongly stimulated by *HN1L* overexpression in a dose-dependent manner ([Figure 6](#fig6){ref-type="fig"}E). We confirmed the regulatory roles of HN1L on the STAT3 signaling pathway through a rescue experiment by co-transfecting SUM159 cells with *HN1L* siRNAs and a plasmid carrying the constitutively active *STAT3-GFP* gene. Cells co-transfected with scrambled siRNA and *GFP* plasmid or siRNA and *STAT3-GFP* plasmid served as controls. *HN1L* gene silencing reduced both the CD44^+^/CD24^−/low^ CSCs and the MSFE in SUM159 cells while the co-transfection with *STAT3-GFP* rescued the cells from the gene silencing, as indicated by the recovered CSC population and the increased MSFE ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). We further examined the activity of *HN1L* on *STAT3* by assessing the stem cell-regulating transcription factors, *KLF4*, *Sox2*, *Sox9*, and *Twist1*, regulated by *STAT3* in an *HN1L* knockdown stable cell line ([@bib49], [@bib47], [@bib15], [@bib25], [@bib45], [@bib39]), whose levels were significantly reduced when *HN1L* levels were depleted by shRNA ([Figure 6](#fig6){ref-type="fig"}F). Furthermore, knocking down *LEPR* was sufficient to reduce TNBC cell migration and MSFE ([Figures 6](#fig6){ref-type="fig"}G and 6H). Altogether, the data support our hypothesis that HN1L is an essential regulator of BCSCs as an upstream regulator of the LEPR-STAT3 signaling pathway.

STAT3 Is the Key Mediator in HN1L Function {#sec2.8}
------------------------------------------

Since *HN1L* is a gene whose gene product has no predictable conserved domains ([@bib32]), the mechanism of action of *HN1L* is enigmatic. The subcellular localization database, COMPARTMENTS, indicated nuclear localization of HN1L with high confidence ([@bib2]). Also, nuclear localization of GFP-tagged HN1L (called L11 in their paper) has been observed ([@bib35]). Based on this, we hypothesized that HN1L may play a regulatory role in gene expression by acting as a transcription factor or co-factor. Hence, chromatin immunoprecipitation coupled with ultra-high-throughput DNA sequencing (ChIP-seq) was performed to identify DNA sequences to which it may bind ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Due to the unavailability of a ChIP-grade HN1L antibody, we overexpressed FLAG-tagged HN1L in SUM159 cells and performed ChIP using anti-FLAG antibodies. HN1L showed 2,249 binding peaks from 10,000 bp upstream to 5,000 bp downstream of the transcription start site, among which 35 genes overlapped with a previously published BCSC gene signature ([@bib8]), 10 genes overlapped with the *HN1L* knockdown gene signature, and 8 genes are well established CSC transcription factors ([@bib21], [@bib12]) ([Figure 7](#fig7){ref-type="fig"}A). When applying overlapped genes in the STRING10 pathway analysis database ([@bib41]), a protein interaction network centered with STAT3 was obtained ([Figure 7](#fig7){ref-type="fig"}B). *STAT3* and *FGFR2* peaks were validated by qPCR ([Figure 7](#fig7){ref-type="fig"}C). Model-based analysis of ChIP-seq (MACS) ([@bib51], [@bib29]) was then used to confirm the peaks found by Hypergeometric Optimization of Motif EnRichment (HOMER) ([@bib16]). Besides the binding peaks found in HOMER, another peak was called by MACS within *LEPR* ([Figure S6](#mmc1){ref-type="supplementary-material"}B) and was also validated by qPCR ([Figure S6](#mmc1){ref-type="supplementary-material"}C). These findings indicate that HN1L may act as a transcription factor through binding to enhancer regions of *STAT3* and other *STAT3* regulators.Figure 7*STAT3* Is a Hub in HN1L Function(A) Venn diagrams showing the overlaps between *HN1L* targets in SUM159 cells and either the BCSC gene signature, the *HN1L* knockdown gene signature, or known CSC transcription factors. Upstream is defined as *HN1L* enrichment 10 kb upstream from the open reading frames of the identified genes.(B) Protein-protein interactions of the overlapped genes from (A) and their association with STAT3 is presented by STRING10. Thicker lines indicate the stronger confidence of associations.(C) ChIP-seq analysis suggested that HN1L binds to upstream sequences of *STAT3* and *FGFR2*. Validation was performed by qPCR, and the y axis represents the relative abundance of DNA fragments in FLAG-ChIP (HN1L) samples over the control IgG-ChIP. n = 3 independent experiments with 3 technical replicates.Error bars represent the SD.

Notably, a pathway analysis on the overlapped genes showed that RNA polymerase II-dependent transcription was a significant biological process involved (p = 0.0000575) ([Figure S6](#mmc1){ref-type="supplementary-material"}D). RNA polymerase II synthesizes not only mRNA but also other RNA molecules including microRNA (miRNA) ([@bib24]). This finding directed us to further investigate the role of HN1L in regulating miRNA. After comparing miRNA expression profiles from PDX BCM2665 xenograft tumors with or without *HN1L* knockdown, we found that miR-150, an important miRNA known to be overexpressed in BCSCsm, was significantly downregulated ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7C) ([@bib18], [@bib20]). To understand the role of miR-150 in the *HN1L-LEPR-STAT3* network, we analyzed all experiment-validated-targets of miR-150 ([@bib17]), together with *LEPR* and *STAT3*, in STRING10. Surprisingly, the miR-150 target genes were clustered with *STAT3* through protein-protein interactions ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Overall, our data indicate that HN1L is able to regulate multiple pathways including *LEPR* signaling and miR-150, which eventually converge into STAT3 to execute its function in maintaining BCSCs.

Discussion {#sec3}
==========

Here, we demonstrate that *HN1L* expression is increased in breast cancer and that its amplification is associated with poor patient prognosis in TNBC. Knockdown of *HN1L* in TNBC cell lines and PDX models significantly reduced BCSC population, lung metastasis, and tumor volume when combined with chemotherapy. The gene signature obtained from patient tumors with *HN1L* knockdown correlated with better survival in TNBC patients. In particular, patients with copy number gains of *HN1L* have a higher rate of relapse and metastasis and lower survival rate. Mechanistically, HN1L works through multiple pathways regulating downstream *STAT3* signaling, which is an established BCSC regulatory pathway ([@bib30], [@bib10], [@bib3], [@bib48]).

Adipose tissue is a major component of breast and is an active endocrine organ secreting cytokines such as leptin to influence the mammary gland microenvironment ([@bib34]). The important role of LEPR in breast cancer has been addressed in multiple studies ([@bib19], [@bib36]), not only in supporting tumor cell proliferation ([@bib46]) and angiogenesis ([@bib36]), but also in maintaining CSC self-renewal properties ([@bib34], [@bib13], [@bib52]). Our data showed that the LEPR pathway is the top canonical pathway associated with *HN1L* knockdown, and depleting LEPR levels sufficiently reduced the BCSC population. Although *LEPR* is a promising drug target, drugs that block LEPR are currently unavailable. As HN1L is an important regulator of *LEPR*, targeting *HN1L* might provide another angle to impair overactive *LEPR* pathways in cancer.

HN1L has multiple cellular functions, including binding to DNA sequences of many BCSC-related genes. Although the details of how HN1L works as a transcription regulator are still unclear, the important role of HN1L in BCSC function necessitates further study on its specific mechanisms. It is noteworthy that among the HN1L-associated genes detected by ChIP-seq, *FGFR2* has been reported to be indispensable for BCSC self-renewal ([@bib22]), suggesting another possible mechanism of HN1L through regulation of *FGFR2* expression.

A common downstream pathway activated by LEPR, miR-150, and FGFR2 is STAT3 ([@bib14]), which has been confirmed here. Although the importance of STAT3 signaling in BCSCs has been established, and the development of *STAT3* inhibitors is being pursued, no STAT3 antagonist is available to-date. Therefore, our findings are crucial since we have identified HN1L as an upstream regulator of *STAT3* and *LEPR* signaling. Therapies targeting HN1L have the potential to interfere with multiple downstream effectors and exert more potent effects on this signaling cascade. Also, upstream inhibition may avoid the activation of compensatory signaling from other downstream effectors causing drug resistance ([@bib44]). Moreover, *STAT3* activation by HN1L is not through a single pathway, as both transcriptional and translational levels of *STAT3* are affected by multiple mechanisms. HN1L inhibition may therefore have a more deleterious impact on *STAT3* action than targeting single pathways. These findings support *HN1L* as an important therapeutic target in TNBC.

In conclusion, our study describes the functions of the gene *HN1L* in BCSC self-renewal. Inhibition of *HN1L* reduces tumor cell proliferation, CSC self-renewal and migration, tumor growth, and metastasis and is associated with improved patient survival. We demonstrate that *HN1L* depletion deactivates *STAT3*-regulated gene networks and reduces BCSC self-renewal. Importantly, *HN1L* overexpression has also been observed in lung, colon, ovarian, pancreatic, prostate, and uterine cancer ([@bib35]). Further studies are required to prove the clinical significance of *HN1L* as a therapeutic target.

Experimental Procedures {#sec4}
=======================

Study Design {#sec4.1}
------------

The objectives of this study were to elucidate unidentified functions and clinical significance of *HN1L*, as a BCSC gene, in *in vitro* and *in vivo* models. First, public breast cancer patient datasets were analyzed to compare the expression of *HN1L* gene and patient outcomes. To investigate the functions of *HN1L* in BCSCs, we utilized two cell line models and one PDX TNBC orthotopic tumor model, *in vivo* limiting dilution, flow-cytometric analysis, gene silencing or overexpression, gene expression microarrays, ChIP-seq analysis, western blot assays, and qRT-PCR. Each experiment was repeated at least two or three times using biological or technical repeats and confirmed by two or three different co-authors. Animals bearing tumors (150--200 mm^3^) were randomly selected into groups, treated, and measured as indicated in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. The endpoints of animal experiments were determined prior to each experiment to mimic clinical treatment schedules. Animals with ulcerated tumors or \>10% body weight loss were excluded from the randomization. We performed blinded bioinformatics or statistical analyses.

Materials and Cell Culture {#sec4.2}
--------------------------

TNBC cell lines (SUM159, MDA-MB-231, and MDA-MB-468) were purchased from ATCC (Manassas, VA, USA). Cells were cultured in DMEM (Invitrogen, Grand Island, NY) with 10% fetal bovine serum (Thermos Scientific Hyclone, Rockford, IL) in a humidified 5% CO~2~ incubator at 37°C. Mammospheres were grown in MammoCult Human Medium with 0.5% MethoCult, both of which were purchased from STEMCELL Technologies (Vancouver, Canada). All CD marker antibodies and mouse immunoglobulin G (IgG) isotype antibodies (APC mouse anti-human CD44, \#559942; CD24 PE-CY7, \#561646; mouse anti-human CD2, \#555327; mouse anti-human CD31, \#555446; mouse anti-human CD18, \#555924; mouse anti-human CD16, \#555407; mouse anti-human CD19, \#555413; mouse anti-human CD45, \#555483; CD140b, \#558821; CD3, \#555333; BD CompBead negative control, \#552843) used in flow-cytometry analysis were purchased from BD Biosciences (San Jose, California). SYTOX Blue Nucleic Acid Stain for dead cell staining was purchased from Invitrogen (catalog \#S34857). Antibodies used for immunoblotting, including anti-STAT3 (catalog \#9132) and anti-pSTAT3-Tyr705 (catalog \#9131), were purchased from Cell Signaling Technology (Danvers, MA). Anti-HN1L (catalog \#HPA041908) and anti-FLAG (catalog \#F3165-1MG) were obtained from Sigma (St. Louis, MO). Anti-leptin receptor antibody (catalog \#AB177469) and anti-leptin antibody (catalog \#AB3583) were purchased from Abcam (Cambridge, MA).

siRNA and shRNA Knockdown {#sec4.3}
-------------------------

The shRNA lentiviral plasmid against *HN1L* was transduced as previously described ([@bib9]). All siRNAs were purchased from Ambion (Austin, TX). Sequences of shRNA and siRNAs are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Mammosphere Formation Assays {#sec4.4}
----------------------------

MSFE was evaluated by mammosphere assay as previously described ([@bib7], [@bib9]). Mammospheres were grown in MammoCult medium with 0.5% methylcellulose. Secondary mammospheres formed in SUM159 cells were counted on day 10 and those in MDA-MB-231 cells were counted on day 14. Detailed methods for these assays are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Fluorescence-Activated Cell Sorting Analysis {#sec4.5}
--------------------------------------------

CD44^+^/CD24^−/low^ population and ALDH activity in cell lines and xenograft tumors were measured by flow cytometry as described previously ([@bib7]) (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"})

Cell Migration and Invasion Assays {#sec4.6}
----------------------------------

Cell migration, cell invasion, and 3D invasion assays were carried out using Cultrex 96-well cell-migration assay (Trevigen, \#3465-096-K), Cultrex 96-well BME cell-invasion assay kit (Trevigen, \#3455-096-K), and Cultrex 3D spheroid cell-invasion assay (Trevigen, \#3500-096-K), respectively, following the manufacturer\'s instructions. Further details can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Overexpression {#sec4.7}
--------------

Cancer cells were transfected with a *HN1L* plasmid tagged with *Myc-DDK* (with *DDK* encoding a *FLAG* sequence) (Origene \#RC209294) using TurboFectin transfection reagent (Origene). An empty pCMV6 vector was used as a control. One to two micrograms of plasmid was used for each transfection in 6-well plates. For a 100-mm dish, we used 20 μg of plasmid and selected cells using 3 mg/mL G418 (Invitrogen) for 3 days. For western blot assay, MDA-MB-231 and MDA-MB-468 cells were serum-starved for 24 hr before harvest.

*In Vivo* Studies {#sec4.8}
-----------------

The Houston Methodist Hospital Research Institute Animal Care and Use Review Office approved this study. All tumor models were developed orthotopically in the mammary fat pad of SCID-Beige mice and handled as described previously ([@bib42], [@bib7], [@bib9]). In brief, after tumors were grown orthotopically to 150--300 mm^3^ in volume, mice were randomized into groups of (i) scrambled siRNA-DOPC, (ii) *HN1L* siRNA-DOPC, (iii) docetaxel + PBS, (iv) docetaxel + scrambled siRNA-DOPC, or (v) docetaxel + *HN1L* siRNA-DOPC. Groups (i), (ii), (iv), and (v) were treated with 5 μg/mouse DOPC nanoliposomal siRNA injection intraperitoneally twice a week for 3 weeks. Groups (iii) to (v) were given 20 mg/kg docetaxel injection intraperitoneally every 2 weeks with the same respective 5 μg/mouse DOPC liposomal siRNAs. DOPC nanoliposomal siRNA was prepared as previously described ([@bib23], [@bib42]). In brief, Scrambled or *HN1L* siRNA was incorporated into DOPC at a ratio of 1:10 (w/w) in the presence of excess tertiary butanol. Liposomal siRNA powder was reconstituted with PBS immediately before *in vivo* administration. More information is available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Western Blot Assay {#sec4.9}
------------------

Western blot assay was performed as previously described ([@bib7], [@bib9]). In brief, all primary antibodies were diluted to 1:1,000 in 5% BSA in a washing buffer (PBS with 1% Tween 20 \[PBST\]), and the secondary antibodies conjugated with horseradish peroxidase to 1:3,000 in 5% skim milk in PBST. Each protein was detected using Western Blotting Luminol Reagent (Santa Cruz Biotechnology). More information is available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Immunohistochemistry {#sec4.10}
--------------------

IHC staining for HN1L target engagement *in vivo* was performed using a protocol similar to one previously published ([@bib9]). In each treatment group, 10 FFPE tumor samples were stained, only 3 of which were randomly chosen to show images due to space limitations.

Gene Expression Microarray Analysis {#sec4.11}
-----------------------------------

Microarrays were performed on 10 snap-frozen tumor samples from scrambled siRNA-treated and *HN1L* siRNA-treated BCM2665 xenografts (5 samples from each treatment group), as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

HN1L Expression and Patient Survival Analysis {#sec4.12}
---------------------------------------------

We downloaded level-3 RNA-seq V2 data from the TCGA and Curtis dataset for *HN1L* from Oncomine ([@bib37]). We normalized the gene expression levels of *HN1L* to the normal breast. Overall survival was estimated for each *HN1L* expression cohort (high versus low) within each database (TCGA and Curtis) by means of the Kaplan-Meier method. Survival was truncated at 10 years. Cohort survival differences were assessed by means of the log-rank test. A low expresser were defined as *HN1L* \< 1.85 and *HN1L* \< 2.0 for the TCGA and the Curtis data, respectively. Additionally, relapse-free survival analysis either with *HN1L* expression or with the *HN1L* knockdown gene signature was performed according to a previously published method and in the same 383-patient TNBC cohort ([@bib6]).

ChIP and ChIP-Seq {#sec4.13}
-----------------

FLAG-tagged HN1L was overexpressed in SUM159 cells. ChIP was carried out using the EZ-ChIP kit (EMD Millipore, \#17-371) following the manufacturer\'s protocol. Further details are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Real-Time PCR {#sec4.14}
-------------

Real-time PCR analysis of *HN1L*, *STAT3*, *LEPR*, *LEP*, and *STAT3* downstream regulators was performed using TaqMan Gene Expression Assays. Validation of ChIP peaks was done in triplicate with the SYBR Green method (Life Technologies, \#4309155). Primer sequences are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Validation of miR-150 in BCM2665 tumors was performed with TaqMan MicroRNA assays following the manufacturer\'s instructions (primer \#000473).

Statistics {#sec4.15}
----------

All *in vitro* data are presented as means ± SD and statistical significance was analyzed by two-tailed Student\'s t test. All experiments had at least 3 replicates and were repeated twice. *In vivo* data are presented as mean ± SEM. Different treatment groups were compared by one-way ANOVA. Patient survival was derived by the Kaplan-Meier method and the log-rank test was used to assess the statistical significance of survival between groups. Cox regression was also used to assess the impact of gene expression values on survival probabilities when analyzing the *HN1L* knockdown gene signature. A p value of less than 0.05 was considered statistically significant.

Author Contributions {#sec5}
====================

Conceptualization, Y.L., D.S.C., and J.C.C.; Methodology, Y.L., D.S.C., M.D.L., and J.C.C.; Investigation, Y.L., D.S.C., J.E.E., J.S., B.D., S.G-P., C.R.-A., H.W., W.Q., and Z.L.; Formal Analysis, Y.L., D.S.C., J.E.E., J.S., S.B., A.P., O.E., A.V., Y.C., and S.W.; Resources, D.S.C., B.D., M.D.L., A.K.S., S.W., G.L.-B., and J.C.C.; Writing -- Original Draft, Y.L. and D.S.C.; Writing -- Review & Editing, D.S.C., D.H.L., J.E.E., J.S., R.R.R., B.D., D.M., and J.C.C.; Supervision, J.C.C.; Funding Acquisition, J.C.C.

Accession Numbers {#app1}
=================

The GEO SuperSeries accession number for this microarray and microRNA array data is GEO: [GSE106200](ncbi-geo:GSE106200){#intref0010}. The GEO accession number for this ChIP-seq data is GEO: [GSE105446](ncbi-geo:GSE105446){#intref0015}.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S7, and Tables S1--S3Document S2. Article plus Supplemental Information

We thank the Flow Cytometry Core of Houston Methodist Research Institute for assisting with flow-cytometry analysis. We also thank the Epigenomics Core of Weill Cornell Medical College for assisting with sequencing of ChIP samples. We thank Dr. Gary Deyter for critical reading and editing of the manuscript. This work was supported by NIH/NCI grants R01 CA138197 and U54 CA149196, the Breast Cancer Research Foundation, the Chan Soon-Shiong Institute for Advanced Health, and Golfers against Cancer.

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and three tables and can be found with this article online at [https://doi.org/10.1016/j.stemcr.2017.11.010](10.1016/j.stemcr.2017.11.010){#intref0020}.

[^1]: Co-first author
